ApprovedFDA approval

Xocova (ensitrelvir)

Shionogi

Marketer take

An oral COVID-19 post-exposure prevention option, unlike treatment-focused Paxlovid, so the audience extends to primary care, urgent care and pharmacies, with seasonal demand.

Sponsor company
Shionogi
Indication
To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
Therapeutic area
Infectious disease
Event
FDA approval
Date
May 29, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move